As head of HHS, Kennedy would lead a sprawling federal department that encompasses more than 100 programs supporting medicine ...
TipRanks on MSN3d
GSK downgraded to Hold from Buy at JefferiesJefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...
On Tuesday, Jefferies revised its stance on GlaxoSmithKline (NYSE ... potential headwinds for Arexvy & Shingrix, as well as the US Medicare Part D redesign, are likely to temper growth. Despite a ...
Hosted on MSN2d
GSK lowered to hold by Jefferies, valuation disconnect citedJefferies said it still regards GSK’s fundamental value as “compelling,” adding that its 2027+ estimates for sales and ...
The drugmaker’s U.S. plans comes on the heels of a rough quarter, with lower vaccine demand driving down Q3 sales by 15% year ...
GSK managed to beat analysts’ revenue predictions ... driven once again by its shingles vaccine Shingrix and HIV therapies sold under the ViiV Healthcare joint venture. Shingrix grew 19% to ...
GlaxoSmithKline places its shingles vaccine Shingrix among its top prospects, with peak sales potential of almost $6 billion. Now, Pfizer and BioNTech are joining forces to try to grab a slice of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback